Nipro Corporation
Nipro Corporation is a pioneering voice in the field of vulnerable plaque and vulnerable patient research. Through focus on product development and strategic clinical research has commercialized the technologies of intravascular near-infrared spectroscopy (NIRS) and extended bandwidth intravascular ultrasound (XB IVUS) in the Makoto Intravascular Imaging System and Dualpro IVUS+NIRS Imaging Catheters. The critical support Nipro for foundational research like the Lipid Rich Plaque (LRP) Study, PROSPECT II, PROSPECT II Absorb, and PACMAN-AMI studies are changing vantage point of intravascular medicine.
The Nipro Corporation, a Japanese corporation established in 1954, is a world-leader in healthcare with over 35,000 employees around the globe. Nipro business covers many areas of the medical glass, pharmaceutical packaging, vascular intervention devices, dialysis, and hospital accessories.